Related Experiment Videos
A novel loop diuretic, torasemide, inhibits thromboxane A2-induced contraction in the isolated canine coronary artery
1Central Research Laboratory, Green Cross Corporation, Osaka, Japan.
Abstract:
We examined the effect of a novel antihypertensive diuretic, torasemide, on the vasoconstriction induced by TXA2 in the isolated canine coronary artery. Carbocyclic thromboxane A2 (CTA2), a stable analogue of the potent coronary vasoconstrictor thromboxane A2, exhibited a slow onset and progressive contraction of isolated canine coronary arteries at 2 x 10(-8) M. Torasemide (10(-7) approximately 10(-4) M) elicited a dose-dependent vasodilating action in the isolated canine coronary arteries contracted by CTA2, whereas indapamide or furosemide had little effect on this preparation. The maximum vasodilating response to torasemide was 45 +/- 12% of vasodilating effect induced by 10(-4) M papaverine. These results suggest that torasemide is a promising antihypertensive agent with a coronary protective effect.
Insights
Torasemide, a novel antihypertensive diuretic, demonstrated a dose-dependent vasodilating effect on canine coronary arteries constricted by thromboxane A2 (TXA2). This suggests torasemide may offer coronary protection alongside its blood pressure-lowering benefits.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Nephrology
Background:
- Thromboxane A2 (TXA2) is a potent coronary vasoconstrictor.
- Antihypertensive diuretics are crucial for managing cardiovascular diseases.
- Novel therapeutic agents with dual actions are of significant interest.
Purpose of the Study:
- To investigate the effect of torasemide on TXA2-induced vasoconstriction in isolated canine coronary arteries.
- To compare the efficacy of torasemide with other diuretics like indapamide and furosemide in this model.
- To assess the potential coronary protective effects of torasemide.
Main Methods:
- Isolated canine coronary artery preparation.
- Induction of vasoconstriction using carbocyclic thromboxane A2 (CTA2).
- Dose-dependent administration of torasemide, indapamide, and furosemide.
- Measurement of vasodilating response and comparison with papaverine.
Main Results:
- CTA2 (2 x 10(-8) M) induced progressive contraction of coronary arteries.
- Torasemide exhibited a dose-dependent vasodilating action (10(-7) to 10(-4) M).
- Indapamide and furosemide showed minimal effects on CTA2-induced contraction.
Conclusions:
- Torasemide possesses significant vasodilating properties in the context of TXA2-mediated vasoconstriction.
- Torasemide demonstrates a potential coronary protective effect.
- Torasemide is a promising antihypertensive agent with potential cardiovascular benefits.